USE OF IL-1 INHIBITORS AND TNF ANTAGONISTS, PARTIALLY IN COMBINATION WITH RECOMBINANT ERYTHROPOIETINS, FOR TREATMENT OF ANEMIA

• Main Authors: COCCIA MARCO A, NEWMARK RICHARD, KAY JONATHAN, MCCABE DOROTHY
• Format: Patent
• Language: English; Japanese
• Published: 09.02.2017
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide methods of treating blood disorders in mammals.SOLUTION: The invention relates to: the use an interleukin-1 (IL-1) inhibitor; the use of an IL-1 inhibitor and an erythropoietin (EPO) receptor agonist; the use of an EPO receptor agonist and a TNF inhibitor; and a composition of an IL-1 inhibitor, and a composition of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist, where the compositions may further contain a therapeutically effective amount of iron.SELECTED DRAWING: None 【課題】哺乳動物における血液障害の治療方法。【解決手段】インターロイキン１（ＩＬ−１）インヒビターの使用。ＩＬ−１インヒビター及びエリスロポエチン（ＥＰＯ）受容体アゴニストの使用。ＥＰＯ受容体アゴニスト及びＴＮＦインヒビターの使用。また、ＩＬ−１インヒビターの組成物、ならびにＩＬ−１インヒビター、ＴＮＦインヒビターおよびＥＰＯ受容体アゴニストの組成物。さらに治療的に有効な量の鉄を含むことができる。【選択図】なし